Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Healthequity (HQY) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Healthequity (HQY) over the last 13 years, with Q4 2025 value amounting to $94.1 million.

  • Healthequity's Cost of Revenue fell 899.85% to $94.1 million in Q4 2025 from the same period last year, while for Oct 2025 it was $416.6 million, marking a year-over-year increase of 447.33%. This contributed to the annual value of $422.5 million for FY2025, which is 1208.78% up from last year.
  • As of Q4 2025, Healthequity's Cost of Revenue stood at $94.1 million, which was down 899.85% from $93.2 million recorded in Q3 2025.
  • Healthequity's 5-year Cost of Revenue high stood at $122.8 million for Q1 2025, and its period low was $76.4 million during Q4 2021.
  • For the 5-year period, Healthequity's Cost of Revenue averaged around $94.1 million, with its median value being $94.1 million (2022).
  • The largest annual percentage gain for Healthequity's Cost of Revenue in the last 5 years was 2393.03% (2025), contrasted with its biggest fall of 899.85% (2025).
  • Over the past 5 years, Healthequity's Cost of Revenue (Quarter) stood at $76.4 million in 2021, then rose by 16.22% to $88.8 million in 2022, then increased by 1.43% to $90.0 million in 2023, then grew by 14.85% to $103.4 million in 2024, then decreased by 9.0% to $94.1 million in 2025.
  • Its Cost of Revenue stands at $94.1 million for Q4 2025, versus $93.2 million for Q3 2025 and $106.5 million for Q2 2025.